Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer
The therapeutic effect of highly malignant triple negative breast cancer (TNBC) is negatively
affected by the formation of tumor cell resistant clone and the severe toxicity of …
affected by the formation of tumor cell resistant clone and the severe toxicity of …
Cancer nanomedicine for combination cancer immunotherapy
Cancer immunotherapy is revolutionizing oncology. However, dose-limiting toxicities and
low patient response rates remain major challenges in the clinic. Cancer nanomedicine in …
low patient response rates remain major challenges in the clinic. Cancer nanomedicine in …
[HTML][HTML] PD-L1 distribution and perspective for cancer immunotherapy—blockade, knockdown, or inhibition
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …
Copackaging photosensitizer and PD-L1 siRNA in a nucleic acid nanogel for synergistic cancer photoimmunotherapy
Y Guo, Q Zhang, Q Zhu, J Gao, X Zhu, H Yu, Y Li… - Science …, 2022 - science.org
Packaging multiple drugs into a nanocarrier with rational design to achieve synergistic
cancer therapy remains a challenge due to the intrinsically varied pharmacodynamics of …
cancer therapy remains a challenge due to the intrinsically varied pharmacodynamics of …
Immunomodulatory nanosystems
Immunotherapy has emerged as an effective strategy for the prevention and treatment of a
variety of diseases, including cancer, infectious diseases, inflammatory diseases, and …
variety of diseases, including cancer, infectious diseases, inflammatory diseases, and …
[HTML][HTML] The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment
K Hudson, N Cross, N Jordan-Mahy… - Frontiers in …, 2020 - frontiersin.org
Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …
Chemically modified platforms for better RNA therapeutics
RNA-based therapies have catalyzed a revolutionary transformation in the biomedical
landscape, offering unprecedented potential in disease prevention and treatment. However …
landscape, offering unprecedented potential in disease prevention and treatment. However …
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
Cancer has complex pathophysiology and is one of the primary causes of death and
morbidity across the world. Chemotherapy, targeted therapy, radiation therapy, and …
morbidity across the world. Chemotherapy, targeted therapy, radiation therapy, and …
Nanomaterials for cancer immunotherapy
Cancer immunotherapy is quickly growing to be the fourth most important cancer therapy,
after surgery, radiation therapy, and chemotherapy. Immunotherapy is the most promising …
after surgery, radiation therapy, and chemotherapy. Immunotherapy is the most promising …
Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy
Nanoscience has long been lauded as a method through which tumor-associated barriers
could be overcome. As successful as cancer immunotherapy has been, limitations …
could be overcome. As successful as cancer immunotherapy has been, limitations …